Outcomes | with OAC (n = 301) | without OAC (n = 531) | Adjusteda HR (95% CI) | P value |
|---|
MACEs | 62 (20.60) | 313 (58.95) | 0.21 (0.15–0.30) | 0.000 |
All-cause death | 29 (9.63) | 258 (48.59) | 0.12 (0.08–0.20) | 0.000 |
Cardiac death | 12(3.99) | 65(12.24) | 0.44(0.22–0.86) | 0.016 |
Non-fatal MI | 0 (0) | 3 (0.56) | 0 (0) | 0.999 |
Non-fatal stroke | 26 (8.64) | 41 (7.72) | 1.03 (0.61–1.77) | 0.900 |
Systemic embolism | 7 (2.33) | 11 (2.07) | 1.30 (0.46–3.63) | 0.619 |
Bleedings | 86 (28.57) | 65 (12.24) | 2.66 (1.81–3.91) | 0.000 |
BARC ≥ 3 | 14 (4.65) | 7 (1.32) | 4.71 (1.75–12.64) | 0.002 |
BARC ≥ 2 | 25 (8.31) | 19 (3.58) | 2.63 (1.36–5.08) | 0.004 |
Net clinical outcomesb | 70(23.26) | 313(58.96) | 0.27(0.19–0.38) | 0.000 |
- MACEs Major adverse cardiovascular events, including all-cause death, non-fatal MI, non-fatal stroke and systemic embolism, OAC Oral anticoagulant, BARC Bleeding Academic Research Consortium, HR Hazard ratio, CI Confidence interval
- aFor MACEs, HR was adjusted by the variables including sex, age, BMI, heart failure, renal insufficiency, chronic renal insufficiency, malignant tumor, chronic obstructive pulmonary disease, previous myocardial infarction, previous stroke, statins, β-blockers, angiotensin receptor blocker, diuretics, proton pump inhibitors, antiplatelet treatment. For bleeding events, HR was adjusted by the variables including sex, age, BMI, heart failure, renal insufficiency, chronic renal insufficiency, malignant tumor, chronic obstructive pulmonary disease, previous myocardial infarction, statins, β-blockers, angiotensin receptor blocker, diuretics, proton pump inhibitors, antiplatelet treatment, previous bleeding; For net clinical outcomes, HR was adjusted by the variables including sex, age, BMI, heart failure, renal insufficiency, chronic renal insufficiency, malignant tumor, chronic obstructive pulmonary disease, previous myocardial infarction, previous stroke, statins, β-blockers, angiotensin receptor blocker, diuretics, proton pump inhibitors, antiplatelet treatment, previous bleeding.
- bNet clinical outcomes were defined as MACEs and BARC ≥ 3 type bleeding events
